ATE432472T1 - Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren - Google Patents

Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren

Info

Publication number
ATE432472T1
ATE432472T1 AT99941990T AT99941990T ATE432472T1 AT E432472 T1 ATE432472 T1 AT E432472T1 AT 99941990 T AT99941990 T AT 99941990T AT 99941990 T AT99941990 T AT 99941990T AT E432472 T1 ATE432472 T1 AT E432472T1
Authority
AT
Austria
Prior art keywords
endogenous
constitutively activated
protein coupled
orphan receptors
coupled orphan
Prior art date
Application number
AT99941990T
Other languages
German (de)
English (en)
Inventor
Dominic Behan
Derek Chalmers
Chen Liaw
I-Lin Lin
Kevin Lowitz
Ruoping Chen
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of ATE432472T1 publication Critical patent/ATE432472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99941990T 1998-07-31 1999-07-30 Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren ATE432472T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (1)

Publication Number Publication Date
ATE432472T1 true ATE432472T1 (de) 2009-06-15

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941990T ATE432472T1 (de) 1998-07-31 1999-07-30 Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren

Country Status (13)

Country Link
EP (1) EP1095275B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002521681A (cg-RX-API-DMAC7.html)
CN (1) CN1231762C (cg-RX-API-DMAC7.html)
AT (1) ATE432472T1 (cg-RX-API-DMAC7.html)
AU (1) AU751080B2 (cg-RX-API-DMAC7.html)
CA (1) CA2338543C (cg-RX-API-DMAC7.html)
DE (1) DE69940923D1 (cg-RX-API-DMAC7.html)
DK (1) DK1095275T3 (cg-RX-API-DMAC7.html)
IL (1) IL140858A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01001176A (cg-RX-API-DMAC7.html)
NO (1) NO20010509L (cg-RX-API-DMAC7.html)
NZ (1) NZ509429A (cg-RX-API-DMAC7.html)
WO (1) WO2000006597A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
CA2402392A1 (en) 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
AU2003219030A1 (en) * 2002-03-22 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
AU2003266238A1 (en) * 2002-08-05 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
AU2003291967A1 (en) * 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220715C (en) * 1995-06-07 2004-11-02 Praecis Pharmaceuticals Incorporated Functional bioassay for g-protein coupled receptor agonists and antagonists
EP0862614A1 (en) * 1995-09-20 1998-09-09 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
EP0965041B1 (en) * 1997-04-14 2009-02-18 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Also Published As

Publication number Publication date
WO2000006597A2 (en) 2000-02-10
CN1323396A (zh) 2001-11-21
NO20010509D0 (no) 2001-01-30
CN1231762C (zh) 2005-12-14
AU5545999A (en) 2000-02-21
WO2000006597A9 (en) 2000-07-13
CA2338543C (en) 2009-12-29
CA2338543A1 (en) 2000-02-10
DE69940923D1 (de) 2009-07-09
AU751080B2 (en) 2002-08-08
NZ509429A (en) 2002-06-28
MXPA01001176A (es) 2005-07-25
WO2000006597A3 (en) 2000-05-18
EP1095275B1 (en) 2009-05-27
JP2002521681A (ja) 2002-07-16
DK1095275T3 (da) 2009-09-28
IL140858A0 (en) 2002-02-10
NO20010509L (no) 2001-03-19
EP1095275A2 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
EE200300191A (et) Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
DE60120748D1 (de) 3-substituierte oxindolderivate als beta-3-agonisten
ATE344241T1 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosine kinasesn, insbesondere von raf kinasen
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DK1584683T3 (da) Human G-protein-koblet orphan receptor RUP3
ATE540970T1 (de) Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
EA200501724A1 (ru) Соединения, специфичные к меланокортиновым рецепторам
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
BR0110079A (pt) Combinação de compostos orgânicos
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
BR0007864A (pt) Composto, e, uso de um composto
PT1086082E (pt) Aminas olefinicas substituidas com arilo e seu uso como agonistas de receptores colinergicos
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
ATE322503T1 (de) Gefrierschutzprotein
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr
NO20010509D0 (no) Endogene konstitutivt aktiverte G-proteinkoblede orfanreseptorer
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
BR0318631A (pt) os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties